Quantum BioPharma Ltd. (NASDAQ: QNTM) has stepped forward to dispel circulating rumors regarding a purported name change and reverse takeover (RTO) involving Unbuzzd Wellness Inc. The biopharmaceutical company emphasized that it has not altered its name to unbuzzd and is not engaged in any RTO transaction with the wellness firm. This clarification comes in the wake of misinformation spread across social media and stock trading platforms, which speculated on a deeper merger or acquisition between the two entities following a recent press release dated May 29, 2025.
Despite the confusion, Quantum BioPharma holds a significant stake in Unbuzzd, including 200 million shares, a 7% royalty agreement on revenue up to $250 million, and a warrant that could increase its ownership to 25%. Additionally, Quantum has provided Unbuzzd with a $1.3 million loan at a 10% interest rate over three years. Unbuzzd, under the leadership of industry veterans John Duffy, a former Coca-Cola executive, and Gerry David, ex-CEO of Celsius Holdings, is currently undergoing PCAOB audits by MNP LLP in preparation for a potential initial public offering (IPO).
Quantum BioPharma also disclosed a forthcoming $20,930 debt settlement with two vendors, expected to be finalized in early June. This announcement underscores the company's ongoing financial and strategic activities separate from Unbuzzd's operations. The clarification from Quantum BioPharma is crucial for investors and stakeholders to understand the distinct paths and financial health of both companies, especially in light of Unbuzzd's IPO preparations and Quantum's focus on neurodegenerative and metabolic disorder treatments.
The implications of this clarification are significant for the biopharmaceutical and investment communities. It highlights the importance of accurate information in the valuation and perception of publicly traded companies. For Quantum BioPharma, maintaining clear boundaries and financial transparency with Unbuzzd ensures that its investors can make informed decisions based on factual data rather than speculative rumors. As Unbuzzd moves closer to its IPO, the clarity provided by Quantum BioPharma serves as a reminder of the complexities and interdependencies within the biotech and wellness industries, where strategic investments and partnerships can often lead to misconceptions without proper communication.
